Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a Healthcare company (Biotechnology) with a market capitalization of $793M. The Maz Rating grades it against the other companies in its sector.
Lexicon Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.78, Lexicon Pharmaceuticals, Inc. trades at 20.6x sales and 4.8x book value. Over the last twelve months it generated about $38M of revenue and a net loss of $65M. It runs a gross margin of 98.6%, an operating margin of -147.4% and a net margin of -161.8%. It shows return on equity of -38.4%, return on invested capital of -25.1% and a free cash flow yield of -8.0%. On the balance sheet: a debt-to-equity ratio of 0.36 and a current ratio of 10.63. Over the past 52 weeks the share price ranged from $1.10 to $2.68, with a beta of 1.08.
Lexicon Pharmaceuticals, Inc. does not currently pay a dividend.
14 Wall Street analyst ratings cover the stock: 5 Buy, 7 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.